Clinical Efficacy and Dynamic CT Observation of Reteplase Combined with Urokinase in Treatment of Middle-risk Pulmonary Embolism
Pulmonary embolism is a clinical and pathophysiological syndrome that causes pulmonary circulatory disorders
due to endogenous or exogenous emboli that block the trunk or branches of the pulmonary artery. This article
compares the clinical efficacy of reteplase and urokinase in the treatment of middle-risk pulmonary embolism.
All patients were divided into the reteplase group and the urokinase group according to different treatment
regimens, and the thrombolytic effects of the two groups were compared and analyzed. Results After treatment,
D-dimer, troponin T, N-Pro BNP and PASP were lower than before treatment (P < 0.05), Pa O2 was higher than
before treatment, and two groups of patients before treatment and treatment There was no significant difference
in D-dimer and troponin T between the 24 hours, but the difference between PaOT2, N-Pro BNP and PASP in
the reteplase group was significantly greater than that in the urokinase group (P<0.05). It can be seen that both
reteplase and urokinase can be used to treat PTE in acute intermediate-risk group. However, in patients with
middle-risk pulmonary embolism during hospitalization, reteplase thrombolytic therapy is superior to urokinase.